Programme
Please note, this is an outline programme and is subject to minor changes.
We acknowledge that this event has received sponsorship funding from pharmaceutical companies . The funding has been used to support the logistical aspects of the event, and the sponsoring companies have had no influence over the content, agenda, or selection of speakers for the main programme . All content is developed independently by the Scientific Committee to ensure that it meets the highest standards of scientific accuracy and objectivity . The sponsored symposia programme includes presentations that have been sponsored by industry and may involve discussion around the products of the sponsoring companies
Day 1 – Thursday 5 September 2024
10.00 — 12.30
Teaching Course 1
Basic Science: From Cells to Circuits: State-of-the-art tools for translational headache research
Parallel Room
| 10.00-10.05 | Welcome & Introduction: | Dr Philip R Holland & Dr Eloisa Rubio Beltran. |
| 10.05-10.30 | Cellular approaches to study headache in the lab | Prof. Arn Van Den Maagdenberg (Leiden University, Netherlands) |
| 10.30-10.50 | Session focussed on opto/chemogenetics and the role of the brainstem LC. | Prof. Tony Pickering (University of Bristol, UK) |
| 10.55-11.20 | Imaging methods to study brain function in preclinical models of migraine. | Dr Philip R Holland (King’s College London) |
| 11.20–11.30 | Open source tools for migraine research. | Dr Hui Zhou Chen (King’s College London, UK) |
| 11.30-11.40 | The potential of differentiated induced pluripotent stem cells to study neurological disease: where biology meets technology. | Dr Jean-Phillipe Frimat (Leiden College, Netherlands) |
| 11.40-11.50 | Chemogenetic modulation of thalamic inhibition. | Dr Eloisa Rubio Beltran (King’s College London, UK) |
| 11.50–12.30 | Interactive discussion and wrap up. |
10.00 — 12.30
Teaching Course 2
Children and Adolescents
Chairs: Amy Gelfand (UC San Francisco, USA) & Prab Prabhakar (Great Ormond Street Hospital & UCL, UK)
Parallel Room
| Premonitory phase in children and adolescents |
Nazia Karsan King’s College London, UK |
|
| Biospychosocial approach to migraine management in children and young people |
Massimiliano Valeriani Ospedale Pediatrico Bambino Gesù, Italy |
10.00 — 12.30
Teaching Course 3
Empowering Nurses / Allied Health Professionals
Chair: Fiona Greenwood (King’s College Hospital NHS Trust, UK)
Parallel Room
| 10:00-10:10 | Introduction |
Fiona Greenwood King’s College London |
| 10:10-10:40 | Transition Clinic- From an Adult and Paediatric Perspective. | |
| 10:10- 10:25 | Paediatric Perspective |
Jo Mortimer and Kate Crumpler GOSH, London. |
| 10:25- 10:40 | Adult Perspective | Helen Delrosario Hull University Teaching Hospital. |
| 10:40-11:00 | Building a Novel Clinic: New Treatments and Access for Patients. |
Claire Winstanley University Hospitals of North Midlands. |
| 11:20- 11:40 | Leading a Team as an Allied Health Professional. |
Anne-Marie Logan St George’s Hospital, London |
| 11:40- 12:00 | Predictors to responding to Treatment/ How do we ensure that we provide patient centred care now that there are more options available? |
Bethany Hill St Thomas’s Hospital, London |
| 12:00- 12:15 |
Panel Discussion (with all Speakers): Question: The importance of allied health professional led clinics and the challenges that are/may be faced. |
12.30 — 14.30
Registration & Networking Lunch
Richmond Suite/Parallel Room
14.00 — 17.30
Teaching Course 4
Getting to Grips with Migraine in Primary Care
Chair: Kay Kennis (Bradford GP Neurology Service, UK)
Parallel Room
| This is a focused educational event delivered by experienced general practitioners with a special interest in headache, all of whom run headache clinics. It will give you more confidence to mange headache and, in particular, migraine. | ||
| A headache overview. What types of headaches do GPs see? | ||
| Children with headache |
Katy Munro National Migraine Centre, UK |
|
| Migraine and women’s health |
Rebecca Walker The Exeter Headache Clinic, UK |
|
| New migraine treatments |
David Watson Hamilton Medical Group, UK |
|
| Surviving the ten-minute headache consultation |
David Kernick The Exeter Headache Clinic, UK |
15.30 — 15.45
Opening Session
Chair: Peter Goadsby
King’s College London
Kensington Suite
15.45 — 16.15
Plenary 1
MacDonald Critchley Lecture
|
Plenary 1 Introduction MacDonald Critchley Lecture |
Mark Weatherall Imperial College, London Antoinette Maassen van den Brink Erasmus MC, Netherlands |
Kensington Suite |
Kensington Suite
16.30 — 17.30
Industry Symposia
Challenge Me! A half decade of monoclonal antibodies for migraine prevention: What we’ve
learnt and what’s next.
Teva Pharmaceuticals Europe B.V.
Kensington Suite
17.30 — 19.30
Welcome Reception
Richmond Suite
Day 2 – Friday 6 September 2024
08.00 — 09.00
Industry Symposia 2
Advances in Pathophysiology and Preventative Treatment of Migraine – Dr Farooq Maniyar and Dr Philip Holland PhD.
AbbVie Ltd.
Kensington Suite
09.00 — 10.30
Plenary 2
From basic through transitional to clinical practice and recommendations
Chair: Mario Peres (São Paulo Headache Center, Brazil)
| Plenary Session 2 From basic through transitional to clinical practice and recommendations |
Chair: Mario Peres São Paulo Headache Center, Brazil |
Kensington Suite |
| Personalised care and biomarkers (Depression and migraine) |
Patricia Pozo-Rosich Vall d’Hebron University Hospital, Spain |
|
| Review data on gender role in response to migraine treatment with acute and prophylactic drugs |
Simona Sacco University of L’Aquila, Italy |
|
| Practice Recommendations |
Francesca Puledda King’s College London, UK |
|
| Hypothalamus role in migraine |
Rami Burstein Harvard Medical School, US |
Kensington Suite
10.30 — 11.00
Coffee Break
Richmond Suite
11.00 — 12.00
Oral Communications 1
Chair: Faisal Mohammad Amin
Copenhagen University Hospital, Denmark
| LB.01 | Efficacy Outcomes from a Phase 3, Randomised, Double- Blind, Placebo-Controlled Study of Fremanezumab for the Preventive Treatment of Episodic Migraine in Children and Adolescents | Xiaoping Ning |
| O.01 | The brainstem locus coeruleus and migraine. | Veronica Munday |
| O.02 | BoNT/A targets sensitized TRPV1-positive DRG neurons at therapeutic concentrations | Mariana Nelson |
| O.03 | Disrupted activation of pain networks during attack imagery in patients with episodic migraine | Raquel Gil-Gouveia |
| O.04 | Glucagon-like peptide-1 receptor agonists for the treatment of migraine: a pilot prospective observational study in a cohort of obese patients | Simone Braca |
| O.05 | Machine learning versus polygenic risk scoring as migraine predictors based on genome-wide genotype data | Antonios Danelakis |
Kensington Suite
12.00 — 13.00
Industry Symposia 3
This promotional symposium has been organised and funded by Lundbeck Ltd.
Lundbeck products will be discussed. The content of this presentation is for healthcare professionals
Kensington Suite
13.00 — 14.30
Lunch
Richmond Suite
13.05 — 13.35
TAC Session (Mini-Oral Presentations)
Diana Wei
King’s College London
| LB.02 | Real-world evidence of clinical and demographic characteristics in cluster headache | Helin Gosalia |
| MO.01 | Efficacy and safety of eptinezumab in patients with episodic cluster headache (ALLEVIATE): A randomized placebo-controlled trial |
Anders Ettrup |
| MO.03 | Role of specific microRNAs in cluster headache: correlation with disease phenotype and neuropeptide levels |
Francescantonio Cammarota |
| MO.04 | Comparison between spontaneous and triggered premonitory symptoms in CH and migraine |
Alicia Gonzalez-Martinez |
| MO.06 | Analysis of MRI-based microstructural and functional resting-state network correlation: insights into the activity of the hypothalamic- thalamo-cortical network in patients with episodic cluster headache. |
Gianluca Coppola |
Kensington Suite
13.35 — 14.30
Digital Poster Booths Session 1
| E-Poster Presentations Session 1A |
E-Poster Presentations Session 1B |
| Chair: Roberta Messina, IRCCS San Raffaele Scientific Institute, Italy |
Chair: Alicia González Martínez, Universidad Autónoma de Madrid, Spain |
Silent Theatres – Richmond Suite
14.30 — 15.30
Parallel Session 1
Migraine Aura: What is it?
Chair: Patricia Pozo-Rosich, Vall d`Hebron University Hospital & Institute of Research, Spain and Philip Holland (King’s College London, UK)
| Parallel Session 1 Migraine Aura: what is it? |
Chairs: Philip Holland |
Kensington Suite |
|
| The bench view | Else Tolner Leiden University Medical Center, Netherlands |
||
| The clinical view | Michele Viana King’s College London, UK |
Kensington Suite
14.30 — 15.30
Parallel Session 2
Chair: Andreas Gantenbein (ZURZACH Care, Switzerland)
| 14:30 – 15:30 |
Parallel Session 2 Data |
Chair: Andreas Gantenbein ZURZACH Care, Switzerland |
Admiral Suite (Level -3, East Wing) |
| Assessing treatment efficacy: the role of randomized clinical trials |
Edoardo Caronna Vall d’Hebron University Hospital, Spain |
||
| Understanding treatment outcomes: the significance of real world data analysis |
Nancy Van Veelan Leiden University Medical Center, Netherlands |
||
| Big data implications for understanding therapy |
Erling Tronvik NorHEAD, NTNU, Norway |
Admiral Suite (Level -3)
15.30 — 16.00
Coffee Break
Richmond Suite
16.00 — 17.00
Plenary 3
Migraine Trust Lecture
Chair: Shazia Afridi (Guy’s and St Thomas’ Foundation Trust, UK)
Speaker: Rami Burstein (Harvard Medical School, USA)
| Plenary 3 – Migraine Trust Lecture |
Chair: Shazia Afridi Guy’s and St Thomas’ Foundation Trust, UK Rami Burstein Harvard Medical School, US |
Kensington Suite |
Kensington Suite
17.00 — 18.00
Industry Symposia 4
Evidence based treatment of migraine with neuromodulation and how does the remote electrical neuromodulation (REN) work
Dr Reddy’s Laboratories (UK) Ltd.
Kensington Suite
Day 3 – Saturday 7 September 2024
07.30 — 08.30
Industry Symposia 5
Kensington Suite
08.30 — 10.00
Plenary 4
Sites of Action of Migraine Medications
Chair: Lars Edvinsson (University Hospital of Lund, Sweden) and Arne May (University of Hamburg, Germany)
| Role of intracranial vasculature and infusion model | Haider Al-Khazali Danish Headache Center, Denmark |
| Key role of the nodes of Ranvier in the trigeminal system | Jacob Edvinsson Lund University, Sweden |
| Role of hypothalamus in migraine initiation | Kuan-Po Peng University Medical Center Hamburg- Eppendorf, Germany |
Kensington Suite
10.00 — 10.30
Coffee Break
Richmond Suite
10.30 — 11.30
Parallel Session 3
Novel Targets and Treatment Challenges
Chair: Raquel Gil-Gouveia (Hospital da Luz, Portugal)
| Vestibular migraine |
David Moreno Ajona King’s College London, UK |
||
| Greater occipital nerve injections |
Debashish Chowdhury GP Pant Institute of Post Graduate Medical Education and Research, New Delhi, India |
||
| Melatonin |
Mario Peres São Paulo Headache Center, Brazil |
||
| 10:30 – 11:30 |
Parallel Session 4 Unravelling biomarkers for migraine treatment: understanding treatment success (and failure) |
Chair: Todd Schwedt Mayo Clinic, USA
|
Admiral Suite, Level – 3, East Wing |
| Non-responders and super- responders to anti-CGRP treatment – what have we learned? |
Piero Barbanti San Raffaele University, Italy |
||
| Delving into biomarkers of treatment response in chronic migraine |
Irene de Boer Leiden University Medical Center, Netherlands |
||
| Imaging biomarkers, can they help unlock insights into treatment success? |
Roberta Messina IRCCS San Raffaele Scientific Institute, Italy |
Kensington Suite
10.30 — 11.30
Parallel Session 4
Unravelling biomarkers for migraine treatment: understanding treatment success (and failure)
Chair: Todd Schwedt (Mayo Clinic, USA)
- Non-Responders and Super-Responders to Anti-CGRP Treatment: What have we learned?: Piero Barbanti
- Delving Into Biomarkers of Treatment Response in Chronic Migraine: Irene de Boer
- Imaging Biomarkers, Can They Help Unlock Insights Into Treatment Success?: Roberta Messina
Admiral Suite (Level -3)
11.30 — 12.30
Industry Symposia 6
From Trials to Treatment: Migraine Clinician Experiences
Pfizer Ltd.
Kensington Suite
12.30 — 13.30
Lunch
30-Minute Product Theatre 2
This promotional symposium has been organised and funded by Lundbeck Ltd.
Lundbeck products will be discussed. The content of this presentation is for healthcare professionals
Kensington Suite
13.30 — 14.30
Digital poster booths Session
| E-Poster Presentations Session 2A |
E-Poster Presentations Session 2B |
| Chair: Edoardo Caronna, Vall d’Hebron University Hospital and Headache Research Group, Spain |
Chair: Roberto De Icco, University of Pavia, Italy |
Silent Theatres- Richmond Suite
| 14:30-15:00 | Coffee Break | Richmond Suite |
13.30 — 14.30
Chair: Shazia Afridi, Guys and St Thomas’ NHS Trust, United Kingdom
| LB.03 | Triptan non-response in a London tertiary headache centre: what can we learn? | Robyn Wilcha | |
| LB.04 | The Safety and Effectiveness of Dual Calcitonin Gene-Related Peptide (CGRP) Therapies for Migraine Treatment: A Focus on Small Molecule Antagonist and Ligand Monoclonal Combinations | Emily (Qu) Sonia Ukai | |
| MO.07 |
Efficacy and safety of Lu AG09222 for migraine prevention in patients with 2–4 previous preventive treatment failures: HOPE, an interventional, randomized, double-blind, parallel-group, placebo-controlled phase 2 trial |
Elin Löf | |
| MO.08 | Practice variation in United Kingdom (UK) neurology management of episodic migraine | Rafi Khan | |
| MO.09 | Effectiveness and predictors of response of intravenous dihydroergotamine in the treatment of primary headache disorders – A service evaluation | Pubudu Amarasena | |
| MO.10 | Switching from ligand to receptor CGRP-mAb or vice versa in non responders: A Controlled Cohort Study | Nancy Van Veelen | |
| MO.11 | OnabotulinumtoxinA (Botox) for Chronic Migraine during pregnancy; experience from Hull (UK) headache clinic over 12 years. | Rafiullah Khan | |
| MO.12 | Real-world Switching Rates of Atogepant Are Lower Than CGRP Monoclonal Antibodies (mAbs) in Patients With Migraine Using Claims Database | Pranav Gandhi | |
|
MO.13 |
Comparison of efficacy and safety of monoclonal antibodies targeting CGRP for Migraine prevention and age- related sub-groups analysis: a 12-months, multicenter, prospective, real-life study | Ilaria Cetta |
Kensington Suite
14.30 — 15.00
Coffee Break
30-minute Product Theatre 3
Dr. Reddy’s Laboratories (UK) Ltd
Ricmond Suite
15.00 — 16.00
Oral Communications 2
Chair: Cristoph Schankin (University of Bern, Switzerland)
| O.08 | Predictors of migraine-related vertigo in adults and children | Nazia Karsan |
| O.09 | Evaluating a New Migraine Scoring System Against Established Metrics | Patricia Pozo-Rosich |
| LB.05 | αCGRP and βCGRP are co- expressed in the trigeminal ganglia | Tayla Rees |
| LB.06 | Stroke etiology and white matter hyperintensities in women with and without migraine | Annelise Wilms |
| LB.07 | The effect of selective adenosine A3 receptor (A3AR) agonists in preclinical models of migraine-like periorbital hypersensitivity | Simon Akerman |
Kensington Suite
16.00 — 17.00
Parallel Session 5
|
16.00-17.00
Parallel sessions |
Parallel Session 5 Barriers to progress in headache care |
Chairs: Rob Music The Migraine Trust, UK & Elena Ruiz de la Torre European Migraine and Headache Alliance (EMHA), Spain |
Kensington Suite |
|
|
Debashish Chowdhury GB Pant Institute of Post Graduate Medical Education and Research, India
Rob Music The Migraine Trust, UK
Elena Ruiz de la Torre European Migraine and Headache Alliance (EMHA), Spain
Philip Holland King’s College London, UK
|
|
|
|
16:00 – 17:00 |
Parallel Session 6 Elevated and low intracranial pressure and headache (and failure) |
Chairs: Koen Paemeleire Ghent University Hospital, Belgium & Alex Sinclair University of Birmingham, UK |
Admiral Suite Level -3, East Wing |
|
|
Should I prescribe semaglutide for IIH? |
Jonathan Hazelhurst University of Birmingham, UK |
|
|
Should I prescribe a CGRP blocking drug in IIH? |
Andreas Yiangou University of Birmingham, UK |
||
|
Should I refer IIH patients for venous stenting? |
Thomas Booth King’s College Hospital NHS Foundation Trust UK |
||
Kensington Suite
16.00 — 17.00
Parallel Session 6
Elevated and Low Intracranial Pressure and Headache
Chairs: Koen Paemeleire (Ghent University Hospital, Belgium) & Alex Sinclair (University of Birmingham, UK)
- Should I prescribe semaglutide for IIH?: Jonathan Hazelhurst
- Should I prescribe a CGRP blocking drug in IIH?: Andreas Yiangou
- Should I refer IIH patients for venous stenting?: Thomas Booth
Admiral Suite (Level -3)
Day 4 – Sunday 8 September 2024
09.30 — 11.00
Plenary Session 5
Exploring the Relationship Between Migraine and Hormones
Chairs: Gisela Terwindt (Leiden University Medical Centre, Netherlands) & Raquel Gil Gouveia (Hospital da Luz, Portugal)
|
Plenary Session 5 Exploring the relationship between migraine and hormones |
Chairs: Gisela Terwindt Leiden University Medical Centre,Netherlands & Raquel Gil-Gouveia , Hospital da Luz, Portugal |
|
Oral contraceptives and migraine: what do you need to know? |
Shazia Afridi Guy’s and St Thomas’ Foundation Trust,UK |
|
Perimenstrual migraine: treatment and prevention |
Britt van der Arend Leiden Headache Center, Netherlands |
|
Migraine and pregnancy: insights, challenges and management strategies |
Simona Sacco University of L’Aquila, Italy |
Kensington Suite
11.00 — 11.30
Coffee Break
Richmond Suite
11.30 — 12.00
Plenary Session 6
|
Plenary Session 6 Cluster Award Lecture Jacob C. A. Edvinsson, Lund University Sweden |
Chair: Roberto De Icco University of Pavia, Italy |
Kensington Suite |
Kensington Suite
12.00 — 12.30
Closing remarks
Kensington Suite